Jentadueto Xr

Physical Activity, Type 2 Diabetes, Diet
Treatment
4 FDA approvals
20 Active Studies for Jentadueto Xr

What is Jentadueto Xr

LinagliptinThe Generic name of this drug
Treatment SummaryLinagliptin is a medication prescribed to treat type 2 diabetes. It works differently than other drugs used to treat the same condition by not being eliminated by the kidneys and binding to proteins in the body in a concentration-dependent manner. The FDA approved linagliptin on May 2, 2011 for use in treating type 2 diabetes.
Tradjentais the brand name
Jentadueto Xr Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Tradjenta
Linagliptin
2011
17

Approved as Treatment by the FDA

Linagliptin, also known as Tradjenta, is approved by the FDA for 4 uses like Type 2 Diabetes Mellitus and Diet .
Type 2 Diabetes Mellitus
Used to treat Type 2 Diabetes Mellitus in combination with Empagliflozin
Diet
Used to treat Diet in combination with Empagliflozin
Physical Activity
Used to treat Exercise in combination with Empagliflozin
Type 2 Diabetes
Used to treat Type 2 Diabetes Mellitus in combination with Empagliflozin

Effectiveness

How Jentadueto Xr Affects PatientsTaking 5mg of linagliptin orally will block the enzyme dipeptidyl peptidase 4 (DPP-4) for at least 24 hours. Blocking DPP-4 increases the amount of a hormone called glucagon-like peptide 1 (GLP-1) in the body, which helps to lower blood sugar levels and hemoglobin levels.
How Jentadueto Xr works in the bodyLinagliptin is a drug that slows the breakdown of two hormones, GLP-1 and GIP. This has the effect of increasing insulin release from the pancreas and decreasing the breakdown of glycogen in the liver. In turn, this helps to regulate your body's blood sugar levels.

When to interrupt dosage

The prescribed dose of Jentadueto Xr relies on the declared state, such as Physical Activity, Diet and Type 2 Diabetes. The measure of dosage is contingent upon the mode of administration (e.g. Tablet - Oral or Tablet) as outlined in the table below.
Condition
Dosage
Administration
Physical Activity
2.5 mg, , 5.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, extended release, Tablet, extended release - Oral
Type 2 Diabetes
2.5 mg, , 5.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, extended release, Tablet, extended release - Oral
Diet
2.5 mg, , 5.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, extended release, Tablet, extended release - Oral

Warnings

Jentadueto Xr has six contraindications. Should any of the conditions in the following table be present, Jentadueto Xr should not be administered.Jentadueto Xr Contraindications
Condition
Risk Level
Notes
Acute Coryza
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
Metabolic acidosis
Do Not Combine
Dialysis therapy
Do Not Combine
Kidney Failure
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Linagliptin may interact with Pulse Frequency
There are 20 known major drug interactions with Jentadueto Xr.
Common Jentadueto Xr Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Linagliptin.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Linagliptin.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Linagliptin.
Alpelisib
Major
The metabolism of Alpelisib can be decreased when combined with Linagliptin.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Linagliptin.
Jentadueto Xr Toxicity & Overdose RiskThe dose of linagliptin does not need to be adjusted for factors such as race, age, weight, sex, or any kidney or liver impairments. While studies of safety and effectiveness in children were not done during the original approval process, recent clinical trials have shown that linagliptin is safe for kids aged 10-18. When tested on animals, linagliptin caused an increased risk of lymphoma in female rats when taken at over 200 times the normal dose. Other than this, the drug was not shown to be damaging to fertility, cause mutations, or affect cell growth.
image of a doctor in a lab doing drug, clinical research

Jentadueto Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Jentadueto Xr?

196 active trials are currently being conducted to examine the potential of Jentadueto Xr to impact Physical Activity, Type 2 Diabetes and Dietary Habits.
Condition
Clinical Trials
Trial Phases
Type 2 Diabetes
167 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Diet
5 Actively Recruiting
Not Applicable, Phase 1
Physical Activity
24 Actively Recruiting
Not Applicable, Phase 1, Phase 2

Patient Q&A Section about jentadueto xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is JENTADUETO XR used for?

"JENTADUETO and JENTADUETO XR tablets can help improve glycemic control in adults with type 2 diabetes mellitus when used with diet and exercise."

Answered by AI

Is Jentadueto the same as metformin?

"Jentadueto is a combination of the oral diabetes medicines linagliptin and metformin. These drugs work together to control blood sugar levels by decreasing glucose production in the liver and reducing absorption of glucose by the intestines."

Answered by AI

How much does Jentadueto cost?

"The cost of Jentadueto will vary depending on the pharmacy, but is typically around $541 for 60 tablets. This price is only for cash paying customers and does not apply to those with insurance plans."

Answered by AI

What are the side effects of JENTADUETO XR?

"The common cold can cause a runny or stuffy nose, diarrhea, cough, hypersensitivity (hives, skin swelling, bronchospasm), decreased appetite, nausea, vomiting, itching, and fatigue."

Answered by AI

Clinical Trials for Jentadueto Xr

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Have you considered Jentadueto Xr clinical trials? We made a collection of clinical trials featuring Jentadueto Xr, we think they might fit your search criteria.Go to Trials
Image of The Worship Center Cristian Church in Birmingham, United States.

Black Impact for Heart Health

18+
Male
Birmingham, AL
The goal of this clinical trial is to evaluate the implementation and effectiveness of the Black Impact program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the Black Impact program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the Black Impact program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.
Waitlist Available
Has No Placebo
The Worship Center Cristian Church
Have you considered Jentadueto Xr clinical trials? We made a collection of clinical trials featuring Jentadueto Xr, we think they might fit your search criteria.Go to Trials
Image of Exercise Metabolism and Inflammation Laboratory in Okanagan, Canada.

Aerobic Exercise with Blood Flow Restriction for Type 2 Diabetes

19 - 64
All Sexes
Okanagan, Canada
The goal of this trial is to learn if blood flow restriction training with treadmill walking is possible for individuals living with type 2 diabetes. It will also learn about how the blood flow restriction with treadmill walking could improve health. The main questions it aims to answer are: Is 6 weeks of treadmill walking with blood flow restriction reasonable for people with type 2 diabetes to perform? Does treadmill walking with blood flow restriction training help manage type 2 diabetes better than just treadmill walking? Researchers will compare treadmill walking with blood flow restriction to treadmill walking without blood flow restriction to see if blood flow restriction works to manage type 2 diabetes based on fitness and blood sugar levels. Participants will: Perform treadmill walking with or without blood flow restriction for 96 minutes a week for 6 weeks. Visit the lab before and after the exercise for tests and questionnaires.
Waitlist Available
Has No Placebo
Exercise Metabolism and Inflammation Laboratory (+2 Sites)Martin Senechal, PhD
Image of Jefferson Health New Jersey in Sewell, United States.

Continuous vs Finger-stick Glucose Monitoring for Type 2 Diabetes in Pregnancy

18+
Female
Sewell, NJ
The purpose of this study is to compare patient adherence to blood sugar monitoring during pregnancy using two different measurement methods in pregnancies complicated by pregestational type 2 diabetes (T2DM). Pregnant patients with T2DM are at risk of having larger babies, babies with low sugar levels in the first 24 hours of life, higher rates of cesarean delivery, stillbirth (death of baby inside the womb), and hypertensive or high blood pressure disorders of pregnancy, such as preeclampsia. Prior studies have shown that treating high blood sugars in pregnancy with medications can reduce these risks. To determine the amount of medication needed, recording of blood sugar levels is necessary. This trial aims to determine whether continuous blood sugar monitors have improved patient recording of blood sugar levels over finger stick blood sugar measurements. Patients involved in the study will be assigned to either: 1. Fingerstick glucose monitoring (FSG) 2. Continuous glucose monitoring (CGM) Patients will be randomize in a 1:1 ratio. FSG Group: blood sugar is tested four times daily - once fasting and two hours after every meal (post-prandial). Blood will be tested using a glucometer, and values will be recorded in a blood sugar log from the time of enrollment to the time of delivery. CGM Group: A CGM sensor will be placed on the patient's arm for blood sugar collection every 3-5 minutes. This data is sent to a phone application from the time of enrollment to the time of delivery. These sensors will need to be replaced every 14 days. Percent adherence will be recorded from the time you were randomized to a study group until delivery.
Recruiting
Has No Placebo
Jefferson Health New Jersey (+1 Sites)
Have you considered Jentadueto Xr clinical trials? We made a collection of clinical trials featuring Jentadueto Xr, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security